用于评估人类免疫缺陷病毒蛋白酶抑制剂产生非结合性高胆红素血症可能性的实用临床前模型。
Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors.
作者信息
Kempf Dale J, Waring Jeffrey F, Morfitt David C, Werner Paige, Ebert Brian, Mitten Michael, Nguyen Bach, Randolph John T, DeGoey David A, Klein Larry L, Marsh Kennan
机构信息
Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064, USA.
出版信息
Antimicrob Agents Chemother. 2006 Feb;50(2):762-4. doi: 10.1128/AAC.50.2.762-764.2006.
Abstract
A practical preclinical model for the hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors has been developed. Indinavir and atazanavir produced significant hyperbilirubinemia, whereas amprenavir, the negative control, was indistinguishable from the ritonavir booster dose. This model was used to disqualify an exploratory protease inhibitor from development.
摘要
一种用于人类免疫缺陷病毒蛋白酶抑制剂所致高胆红素血症的实用临床前模型已被开发出来。茚地那韦和阿扎那韦可导致显著的高胆红素血症，而作为阴性对照的安普那韦与利托那韦增效剂量之间没有差异。该模型被用于淘汰一种处于研发阶段的探索性蛋白酶抑制剂。
相似文献
1
Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors.用于评估人类免疫缺陷病毒蛋白酶抑制剂产生非结合性高胆红素血症可能性的实用临床前模型。
Antimicrob Agents Chemother. 2006 Feb;50(2):762-4. doi: 10.1128/AAC.50.2.762-764.2006.
2
Mechanism of indinavir-induced hyperbilirubinemia.茚地那韦诱导高胆红素血症的机制。
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12671-6. doi: 10.1073/pnas.231140698. Epub 2001 Oct 16.
3
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.采用等度高效液相色谱法结合紫外和荧光检测同时测定人血浆中的8种HIV蛋白酶抑制剂：安普那韦、茚地那韦、阿扎那韦、利托那韦、洛匹那韦、沙奎那韦、奈非那韦和M8 - 奈非那韦代谢物。
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jan 1;845(1):51-60. doi: 10.1016/j.jchromb.2006.07.068. Epub 2006 Sep 25.
4
Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.胆酰甘氨酰胺荧光素在夹心培养的大鼠肝细胞中的细胞积累：动力学特征、转运机制及人类免疫缺陷病毒蛋白酶抑制剂的作用
Drug Metab Dispos. 2008 Jul;36(7):1315-21. doi: 10.1124/dmd.107.019398. Epub 2008 Apr 17.
5
Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.人类免疫缺陷病毒/获得性免疫缺陷综合征患者的感觉神经病变：蛋白酶抑制剂介导的神经毒性
Ann Neurol. 2006 May;59(5):816-24. doi: 10.1002/ana.20816.
6
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.在人类免疫缺陷病毒阴性受试者中同时给予福沙普那韦和阿扎那韦（不联用利托那韦）的药代动力学
Pharmacotherapy. 2009 Aug;29(8):937-42. doi: 10.1592/phco.29.8.937.
7
Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate. 2003 Jun-Jul;15(4):1-2.
8
Systems pharmacology modeling of drug-induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters.药物性高胆红素血症的系统药理学建模：区分肝毒性与酶/转运体抑制作用
Clin Pharmacol Ther. 2017 Apr;101(4):501-509. doi: 10.1002/cpt.619. Epub 2017 Feb 17.
9
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.在合并感染艾滋病毒和肝炎病毒的患者中，包括阿扎那韦/利托那韦在内的抗逆转录病毒联合疗法的肝脏毒性：既往肝纤维化的影响
J Antimicrob Chemother. 2008 Apr;61(4):925-32. doi: 10.1093/jac/dkn045. Epub 2008 Feb 14.
10
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.在人类免疫缺陷病毒患者中换用基于阿扎那韦-利托那韦的高效抗逆转录病毒疗法后的降脂疗效及安全性
Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.
引用本文的文献
1
Hyperbilirubinaemia in HIV-HCV co-infected patients on antiretroviral therapy: drug effect or liver disease severity?接受抗逆转录病毒治疗的HIV-HCV合并感染患者的高胆红素血症：药物作用还是肝脏疾病严重程度？
BMJ Open Gastroenterol. 2016 Mar 2;3(1):e000072. doi: 10.1136/bmjgast-2015-000072. eCollection 2016.
2
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.新型人类免疫缺陷病毒1型蛋白酶抑制剂A-790742的特性
Antimicrob Agents Chemother. 2008 Apr;52(4):1337-44. doi: 10.1128/AAC.01132-07. Epub 2008 Jan 22.
3
Biomarkers, metabonomics, and drug development: can inborn errors of metabolism help in understanding drug toxicity?生物标志物、代谢组学与药物研发：先天性代谢缺陷有助于理解药物毒性吗？
AAPS J. 2007 Jul 20;9(3):E284-97. doi: 10.1208/aapsj0903031.
本文引用的文献
1
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.阿扎那韦及其他HIV蛋白酶抑制剂对尿苷二磷酸葡萄糖醛酸基转移酶的体外抑制作用及其该特性与体内胆红素葡萄糖醛酸化的关系。
Drug Metab Dispos. 2005 Nov;33(11):1729-39. doi: 10.1124/dmd.105.005447. Epub 2005 Aug 23.
2
Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.抑制人类有机阴离子转运多肽OATP 1B1作为药物性高胆红素血症的一种机制。
Chem Biol Interact. 2004 Nov 20;150(2):179-87. doi: 10.1016/j.cbi.2004.08.008.
3
Mechanism of indinavir-induced hyperbilirubinemia.茚地那韦诱导高胆红素血症的机制。
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12671-6. doi: 10.1073/pnas.231140698. Epub 2001 Oct 16.
4
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.与利托那韦共同给药对人免疫缺陷病毒蛋白酶抑制剂的药代动力学增强作用。
Antimicrob Agents Chemother. 1997 Mar;41(3):654-60. doi: 10.1128/AAC.41.3.654.
Zotero 插件